EdgeMarket › What Sphera Funds Management Ltd. reported owning
What Sphera Funds Management Ltd. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
629.7MPositions
96Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics, Inc. | 36.3M | 5.8% | 1.3M | 25.65 | +65.7% |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 34.2M | 5.4% | 1.1M | 37.34 | +112.0% |
| TSEM TOWER SEMICONDUCTOR LTD | 25.6M | 4.1% | 145.7K | 222.59 | +344.7% |
| NVMI NOVA LTD. | 23.2M | 3.7% | 53.4K | 376.99 | +53.0% |
| BBIO BridgeBio Pharma, Inc. | 18.2M | 2.9% | 245.2K | 81.50 | +66.7% |
| BIIB BIOGEN INC. | 17.0M | 2.7% | 92.5K | 216.78 | +56.0% |
| RARE Ultragenyx Pharmaceutical Inc. | 17.0M | 2.7% | 809.3K | 25.83 | -12.0% |
| SNDX Syndax Pharmaceuticals Inc | 16.9M | 2.7% | 724.6K | 19.65 | +24.8% |
| COGT Cogent Biosciences, Inc. | 16.0M | 2.5% | 416.3K | 36.73 | +209.6% |
| SNY Sanofi | 13.0M | 2.1% | 269.5K | 45.85 | -9.3% |
| AZN ASTRAZENECA PLC | 12.3M | 2.0% | 62.5K | 165.98 | — |
| unmapped CUSIP 03152W109 | 8.7M | 1.4% | 603.4K | — | — |
| CLBT Cellebrite DI Ltd. | 8.7M | 1.4% | 631.5K | 11.05 | -28.6% |
| unmapped CUSIP 03753U106 | 8.6M | 1.4% | 214.9K | — | — |
| PANW Palo Alto Networks Inc | 8.5M | 1.3% | 52.8K | 357.87 | +94.0% |
| LLY ELI LILLY & Co | 8.3M | 1.3% | 9.0K | 1,255.40 | +78.0% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 8.2M | 1.3% | 866.5K | 9.55 | +14.0% |
| CAMT CAMTEK LTD | 8.0M | 1.3% | 53.0K | 146.81 | +78.1% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 7.9M | 1.3% | 139.9K | 66.70 | +15.1% |
| CLDX Celldex Therapeutics, Inc. | 7.7M | 1.2% | 243.6K | 40.38 | +93.3% |
| ORA ORMAT TECHNOLOGIES, INC. | 7.6M | 1.2% | 68.2K | 108.38 | +17.4% |
| XENE Xenon Pharmaceuticals Inc. | 7.4M | 1.2% | 127.0K | 60.77 | +61.5% |
| unmapped CUSIP 834203309 | 7.2M | 1.1% | 216.3K | — | — |
| TNGX Tango Therapeutics, Inc. | 7.2M | 1.1% | 343.6K | 23.88 | +253.8% |
| JNJ JOHNSON & JOHNSON | 7.0M | 1.1% | 28.8K | 270.24 | +51.1% |
| unmapped CUSIP 83417MAE4 | 6.9M | 1.1% | 4.0M | — | — |
| IMTX Immatics N.V. | 6.8M | 1.1% | 696.1K | 8.93 | +59.5% |
| TRVI Trevi Therapeutics, Inc. | 6.8M | 1.1% | 574.0K | 17.96 | +142.0% |
| ORIC Oric Pharmaceuticals, Inc. | 6.8M | 1.1% | 537.6K | 14.20 | +49.3% |
| MAZE Maze Therapeutics, Inc. | 6.8M | 1.1% | 227.3K | 29.43 | +118.3% |
| GSK GSK plc | 6.7M | 1.1% | 122.0K | 52.41 | +30.8% |
| AMZN AMAZON COM INC | 6.7M | 1.1% | 31.9K | 258.63 | +15.6% |
| ABBV AbbVie Inc. | 6.6M | 1.0% | 30.3K | 264.96 | +26.7% |
| AAOI APPLIED OPTOELECTRONICS, INC. | 6.2M | 1.0% | 73.4K | 124.82 | +469.2% |
| ELVN Enliven Therapeutics, Inc. | 6.0M | 1.0% | 153.3K | 59.82 | +204.3% |
| MRK Merck & Co., Inc. | 5.8M | 0.9% | 48.6K | 152.55 | +80.2% |
| VOR Vor Biopharma Inc. | 5.7M | 0.9% | 321.9K | 23.36 | -46.9% |
| ACAD ACADIA PHARMACEUTICALS INC | 5.7M | 0.9% | 256.2K | 29.50 | +18.3% |
| NVS NOVARTIS AG | 5.7M | 0.9% | 37.0K | 158.86 | +24.8% |
| ELDN Eledon Pharmaceuticals, Inc. | 5.5M | 0.9% | 1.8M | 3.45 | +33.7% |
| ENPH Enphase Energy, Inc. | 5.4M | 0.9% | 142.4K | 38.61 | +8.2% |
| RVMD Revolution Medicines, Inc. | 5.4M | 0.9% | 55.1K | 209.46 | +479.3% |
| PFE PFIZER INC | 5.2M | 0.8% | 186.0K | 28.07 | +10.6% |
| BHVN Biohaven Ltd. | 5.0M | 0.8% | 594.0K | 13.85 | -5.8% |
| FBRX Forte Biosciences, Inc. | 4.8M | 0.8% | 185.0K | 76.92 | +554.1% |
| HELP CYBIN INC. | 4.7M | 0.8% | 987.1K | 12.59 | +90.8% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 4.7M | 0.8% | 9.0K | 516.74 | +31.9% |
| SRRK Scholar Rock Holding Corp | 4.6M | 0.7% | 94.3K | 56.50 | +64.2% |
| NVO NOVO NORDISK A S | 4.4M | 0.7% | 120.7K | 46.74 | -13.9% |
| MDWD MediWound Ltd. | 4.4M | 0.7% | 273.2K | 13.21 | -24.3% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →